Pril-series drugs are one of the commonly used antihypertensive drugs in clinical practice, ending with "Pril", such as perindopril and enalapril. Pril-series drugs are called Angiotensin-converting enzyme (ACE) inhibitors, are medicines that help relax the veins and arteries to lower blood pressure.

The global Pril-series Drugs API market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Pril-series Drugs API Industry Forecast” looks at past sales and reviews total world Pril-series Drugs API sales in 2023, providing a comprehensive analysis by region and market sector of projected Pril-series Drugs API sales for 2024 through 2030. With Pril-series Drugs API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pril-series Drugs API industry.

This Insight Report provides a comprehensive analysis of the global Pril-series Drugs API landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue
• Market share
• Latest development
• M&A activity

This report also analyzes the strategies of leading global companies with a focus on Pril-series Drugs API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pril-series Drugs API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pril-series Drugs API and breaks down the forecast by:

1. Type
2. Application
3. Geography
4. Market size

The United States market for Pril-series Drugs API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

The China market for Pril-series Drugs API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

The Europe market for Pril-series Drugs API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Pril-series Drugs API players cover:

• Huahai Pharmaceutical
• Zhejiang Changming Pharmaceutical
• Dr. Reddy's Laboratories
• Glenmark
• ScinoPharm

In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Pril-series Drugs API market by:

• Product type
• Application
• Key manufacturers
• Key regions and countries

Segmentation by Type:

• Enalapril
• Lisinopril
• Captopril
• Ramipril
• Perindopril
• Benazepril
• Others

Segmentation by Application:

• Tablets
• Capsules
• Others

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration:

• Huahai Pharmaceutical
• Zhejiang Changming Pharmaceutical
• Dr. Reddy's Laboratories
• Glenmark
• ScinoPharm
• Novartis Pharma
• Sun Pharmaceutical
• Farmhispania
• Medichem
• Hetero
• Siegfried Evionnaz
• Changzhou Pharmaceutical Factory
• Chongqing Southwest No. 2 Pharmaceutical Factory
• Ningbo Menovo Pharmaceutical

Key Questions Addressed in this Report:

• What is the 10-year outlook for the global Pril-series Drugs API market?
• What factors are driving Pril-series Drugs API market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Pril-series Drugs API market opportunities vary by end market size?
• How does Pril-series Drugs API break out by Type, by Application?